XNCR
USDXencor Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$14.340
Максимум
$14.340
Минимум
$13.620
Объем
0.91M
Фундаментальные показатели компании
Рыночная капитализация
972.6M
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
1.15M
Биржа
NGM
Валюта
USD
52-недельный диапазон
Связанные новости
Barclays Upgrades Xencor to Overweight, Raises Price Target to $23
Barclays analyst Etzer Darout upgrades Xencor from Underweight to Overweight and raises the price target from $6 to $23.
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $18
RBC Capital analyst Leonid Timashev maintains Xencor with a Outperform and raises the price target from $15 to $18.
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-- Management to host webcast and conference call on Friday, October 24, 2025 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and
Связанные акции
LFUS
Littelfuse Inc.
ALVR
AlloVir Inc.
OCFC
OceanFirst Financial Corp.
MTNB
Matinas Biopharma Holdings Inc.
PTA
Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund Common Shares of Beneficial Interest
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.